Invitation to a webcast presentation regarding SenzaGen’s acquisition of Alcyomics

SenzaGen has entered into an agreement to acquire Alcyomics, as announced earlier today, and therefore invites you to a webcast presentation on Thursday October 29 at 13:00. The presentation will be hosted by SenzaGen’s President and CEO, Peter Nählstedt, and will be followed by a Q&A session moderated by Rodney Alfvén, partner at Hallvarsson & Halvarsson.

The presentation will be held in Swedish.

Time: Thursday, October 29, at 13:00 CET.

Webcast
If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions.
https://senzagen.events.inderes.com/press-conference-2026

Teleconference
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. https://events.inderes.com/senzagen/press-conference-2026/dial-in

The presentation can also be viewed later on SenzaGen's website: https://senzagen.com/presentations/

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Tel: +46 46-275 62 00

About us

SenzaGen is a fast‑growing company in the field of non‑animal chemical safety testing. Through ground-breaking innovations that better reflect human biology, the company works toward its vision of advancing and protecting human health while replacing the use of animals in testing. With GLP‑certified laboratories in Sweden and Italy, SenzaGen is driving the shift toward safer and more ethically sustainable testing practices. At the center of the offering is the company’s unique GARD® platform, which combines genomics and machine learning to deliver highly reliable decision‑support data for assessing skin and respiratory sensitization. SenzaGen’s strategy combines commercial focus, regulatory progress, and innovation to support long‑term profitable growth. SenzaGen is headquartered in Lund, Sweden, with subsidiaries in Italy and the United States. For more information, visit www.senzagen.com. 

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

Attachments

Invitation to a webcast presentation regarding SenzaGen’s acquisition of Alcyomics